Navigation Links
Cellectis bioresearch Makes Genome Engineering Affordable for All Users

PARIS, Feb. 28, 2011 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), has today launched TALEN Access™, the first fee-for-service custom TALEN(1).

Recognized as a pioneer in the development of innovative research products for genome customization, Cellectis bioresearch brings today the life sciences community a new tool for specifically modifying genes in any type of cell.

The service will start with the TALEN Access™ offer, which provides a pair of TALENs for 5,000 euro/US$, delivered in less than 3 weeks.

"What we are offering here is a true commercial revolution," said Luc Selig, VP Sales and Marketing at Cellectis bioresearch. "We are keeping our promise to make genome customization affordable for the hundred of thousands academic research labs."

For further information or to place orders, please go to

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

The kits can be purchased online from More information on the website.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at

Follow Cellectis on Twitter at  


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with the IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) TALEN: Transcription Activator-Like Effector Nuclease

SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellectis In-Licenses Induced Pluripotent Stem Cell Technology From iPS Academia Japan
2. Cellectis Publishes Its Financial Statement for the First Half of 2010
3. Cellectis bioresearch Announces Establishment of Subsidiary in the US
4. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
5. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
6. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
7. SAP Makes Life Easier for Patients and More Efficient for Healthcare Providers Through New Technology
8. Pinnaclife Makes it Official With Launch Slated for March 1st
9. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
10. US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
11. Panasonic Makes Investment in Houston-based CardioNexus Corp.
Post Your Comments:
(Date:11/30/2015)... VIEW, Calif. , Nov. 30, 2015 ... been the norm in U.S. medical imaging ... The increasingly popular accountable care payer-provider contracts ... models and, in their wake, alter provider-vendor ... quality-based payments will push forward new purchasing ...
(Date:11/30/2015)... and SAN DIEGO , ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... for filing the New Drug Application (NDA) for an ... release formulation will offer patients a chronic weight management ... ® ) is currently approved as an adjunct to ...
(Date:11/30/2015)... and ST. LOUIS , Nov. 30, ... ESRX ) today announced an early renewal of ... began in 1999, will now extend through at least ... After evaluating pharmacy benefit manager capabilities during a ... Scripts continues to offer the best health plan integration ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The recently published 32nd Annual Report of ... that in 2014, someone called a poison center about every 11 seconds. America’s ... human exposure cases. , The American Association of Poison Control Centers (AAPCC) maintains ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation for Breast ... and prevention—is joining forces with the award-winning creator and writer of Downton Abbey ... 7, 2015 at the Union League of Philadelphia. , The benefit, titled ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting ... so for a child’s exposure limits. , The original Nov 2015 CR story ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about ... baby had high blood pressure due to loud noises," she said, "so I decided ... noise pollution as well as radio waves and microwaves." , The baby BABY MUFF ...
(Date:11/30/2015)... CHICAGO (PRWEB) , ... November ... ... introduced two new additions to its industry-leading suite of automated breast density ... of North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth ...
Breaking Medicine News(10 mins):